Sudeep Pharma Q1 Results FY27: PAT at Rs 40 Cr for June 2026 Quarter

Sudeep Pharma Q1 results FY27: PAT Rs 40 Cr (+29.80% YoY) | Revenue Rs 158 Cr (+26.70% YoY) | Gross Margin 31.6% | Stock Rs 871.8 (up 0.48%)

The Sudeep Pharma Q1 results FY27 show consolidated revenue of Rs 158 Cr for the quarter ended 30 June 2026, +26.70% year on year from Rs 124 Cr in Q1 FY26, as Sudeep Pharma reported its numbers on 4 August 2026. Sudeep Pharma posted pat of Rs 40 Cr for the quarter, against Rs 31 Cr in Q1 FY26, a change of +29.80%. Shares traded around Rs 871.8 on the NSE, up 0.48% on the day.

The June 2026 quarter played out against a broadly stable macro backdrop, contained inflation, a supportive monsoon outlook, and resilient domestic consumption, though global uncertainty around tariffs and commodity prices kept sector-level variability elevated. Against that backdrop, the Sudeep Pharma Q1 results FY27 give investors the first hard data point for FY27. This article breaks down what happened at the revenue, gross profit, and net profit line, what the numbers mean for the full year, and what questions investors should be asking before making any portfolio decision.

Click Here – Get Free Investment Predictions

Sudeep Pharma Q1 results FY27 Financial Highlights

All figures are consolidated numbers in Rs Crore as reported by Sudeep Pharma for Q1 FY27 (April to June 2026). The table compares them against the same quarter in FY26.

Sudeep Pharma Q1 results FY27 Performance Analysis

Sudeep Pharma delivered steady topline progress this quarter. Revenue grew +26.70% year on year to Rs 158 Cr, against Rs 124 Cr in Q1 FY26. The growth is organic and in line with the company’s stated ambitions for FY27, suggesting the business is executing broadly on plan.

The gross profit line was the weak spot this quarter. Sudeep Pharma reported Rs 50 Cr (31.6% margin) against Rs 40 Cr a year ago, a change of +25.32%. Whether this margin compression is structural or cyclical is the key question investors should press on.

Sudeep Pharma converted its revenue growth into earnings gains. Net profit (pat) grew +29.80% to Rs 40 Cr from Rs 31 Cr a year earlier. Consistency here over several quarters would support a valuation re-rating.

Check the Univest Screener for Live Data

Sudeep Pharma Q1 results FY27: Key Business Factors

1. Revenue: What Drove the Quarter

Sudeep Pharma reported revenue of Rs 158 Cr against Rs 124 Cr in Q1 FY26, a change of +26.70%. Understanding this revenue figure requires context: in the pharmaceuticals sector, volume growth and realisation per unit are both drivers, and the aggregate revenue number is the product of both. Investors tracking Sudeep Pharma should check the investor presentation or earnings call commentary for the volume-versus-pricing split underlying this quarter’s topline.

2. Gross Profit and Margin Trends

Gross margin was broadly stable at 31.6% versus 32.3% in Q1 FY26. Stability in this line is a credible outcome for the pharmaceuticals sector, where raw material and API cost volatility, regulatory approvals and pricing pressure in key markets can move margins sharply quarter to quarter. Sustained gross margin stability gives management a predictable base to work from as it invests in growth for the rest of FY27.

3. Net Profit and Earnings Quality

Sudeep Pharma posted pat of Rs 40 Cr for the June 2026 quarter, against Rs 31 Cr in Q1 FY26, a change of +29.80%. This bottom line figure is what drives earnings per share and, ultimately, the P/E multiple at which the stock trades. Analysts will now update their FY27 EPS estimates using this Q1 run rate, adjusted for any seasonal factors and guidance management provides on the earnings call.

Sudeep Pharma Q1 results FY27 vs Analyst Expectations

Whether the Sudeep Pharma Q1 results FY27 met, beat, or missed analyst forecasts will determine how quickly institutional investors reposition their holdings.

Analyst estimates for the Sudeep Pharma Q1 results FY27 varied ahead of the announcement. The actual revenue of Rs 158 Cr and PAT of Rs 40 Cr now set the benchmark against which FY27 consensus estimates will be revised. When a company beats on both revenue and profit, the stock typically sees buying in the first post-result session. A miss on both tends to trigger selling and downgrades. A mixed print stays range-bound until the earnings call provides clarity. Investors tracking Sudeep Pharma should check live analyst verdict updates on the Univest Screener alongside the stock price movement to contextualise the post-result market reaction.

Sudeep Pharma Dividend Update

No specific dividend announcement was confirmed as part of the Sudeep Pharma Q1 results FY27 snapshot. Most companies declare dividends at the annual board meeting rather than with quarterly results. Investors tracking Sudeep Pharma for its dividend yield should check the official NSE or BSE exchange filing, or the Univest Screener, for the latest record date and payout details.

Sudeep Pharma Outlook After Q1 results FY27

The Sudeep Pharma Q1 results FY27 establish the Q1 FY27 baseline for revenue at Rs 158 Cr and PAT at Rs 40 Cr. Whether FY27 ends up as a year of acceleration depends on two variables: whether the growth in revenue sustains through Q2 to Q4, and whether margin trends improve, stabilise, or deteriorate relative to this quarter’s gross profit margin of 31.6% . Management guidance on the earnings call will be the single most important datapoint for updating FY27 forecasts. Investors should also track macroeconomic inputs relevant to the pharmaceuticals sector through the rest of the year.

Investors tracking Sudeep Pharma after the Q1 FY27 numbers should focus on three things heading into Q2 FY27: whether the growth in revenue sustains, whether the improvement trend in profit continues without the help of one-off items, and whether management’s guidance for FY27 holds. A results conference call or investor presentation, if scheduled, will be the primary opportunity for management to address these questions.

Should You Buy Sudeep Pharma After the Q1 results FY27?

The question most investors ask after any quarterly result is whether it changes the investment case. The Sudeep Pharma Q1 results FY27 show revenue of Rs 158 Cr, gross profit of Rs 50 Cr, and PAT of Rs 40 Cr. Whether these numbers justify buying, holding, or selling depends on the price the stock is trading at (Rs 871.8 at the time of this result), the FY27 consensus earnings estimate, and whether this Q1 run rate is sustainable for the remaining three quarters. Investors should check the P/E, P/B, and EV/EBITDA multiples on the Univest Screener against sector peers before deciding. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.

Sudeep Pharma Share Price After the Q1 results FY27

Sudeep Pharma shares traded at Rs 871.8 on the NSE, up 0.48% on the day the Sudeep Pharma Q1 results FY27 were in focus. Post-result price moves are often driven by event-driven traders who have built positions ahead of the result and unwind them regardless of outcome. Investors should look past the first-session move and focus on whether the fundamental trend in revenue and earnings has changed. The 52 week high, 52 week low, and technical support levels for Sudeep Pharma are available on the Univest Screener for investors who want to time their entry or exit.

Download the Univest iOS App or Univest Android App to track Sudeep Pharma live share price and upcoming quarterly results.

Key Risks to Track After the Sudeep Pharma Q1 results FY27

Investors should weigh these risks carefully before acting on the Q1 data.

1. Sector and Margin Risk

Sudeep Pharma operates in the pharmaceuticals sector, which is exposed to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets. A reversal of the trends visible in the Sudeep Pharma Q1 results FY27, particularly on the gross profit margin, could put the full-year FY27 earnings estimate at risk.

2. Single-Quarter vs Trend Risk

A single quarterly result can be distorted by working capital cycles, timing of receivables, or one-off costs and reversals that do not repeat. The Sudeep Pharma Q1 results FY27 should be read alongside Q2 data before drawing firm conclusions.

3. Macro and External Risk

Macro factors including RBI rate decisions, INR/USD movements, input commodity prices, and rural versus urban demand mix can shift the environment in the pharmaceuticals sector faster than company-level actions can compensate for.

Conclusion

Investors researching the Sudeep Pharma Q1 results FY27 will find the key numbers, revenue, gross profit, and net profit, summarised in the table above and analysed in each section of this article.

The Sudeep Pharma Q1 results FY27 show consolidated revenue of Rs 158 Cr (+26.70% year on year) and PAT of Rs 40 Cr (versus Rs 31 Cr in Q1 FY26). Gross profit came in at Rs 50 Cr at a margin of 31.6%, improving from Rs 40 Cr a year earlier. Revenue growth and a stronger bottom line were the two key themes of the quarter. Investors tracking Sudeep Pharma should use the Sudeep Pharma Q1 results FY27 as the baseline and watch Q2 FY27 results, due around October 2026, as the first confirmation of whether these trends are durable. Always consult a SEBI-registered advisor before acting on any quarterly result.

Frequently Asked Questions on Sudeep Pharma Q1 results FY27

What were the Sudeep Pharma Q1 results FY27?

Ans. Sudeep Pharma reported revenue of Rs 158 Cr (+26.70% YoY) and PAT of Rs 40 Cr for Q1 FY27 (quarter ended 30 June 2026), against Rs 31 Cr in Q1 FY26.

What is the PAT in the Sudeep Pharma Q1 results FY27?

Ans. PAT in the Sudeep Pharma Q1 results FY27 stood at Rs 40 Cr, compared with Rs 31 Cr in Q1 FY26, a change of +29.80%.

What was the revenue in the Sudeep Pharma Q1 results FY27?

Ans. Revenue in the Sudeep Pharma Q1 results FY27 was Rs 158 Cr, a change of +26.70% from Rs 124 Cr in Q1 FY26.

What was the gross profit in the Sudeep Pharma Q1 results FY27?

Ans. Gross profit in the Sudeep Pharma Q1 results FY27 was Rs 50 Cr (31.6% margin), compared with Rs 40 Cr in Q1 FY26, a change of +25.32%.

Did Sudeep Pharma declare a dividend with the Q1 results FY27?

Ans. No dividend was confirmed as part of the Sudeep Pharma Q1 results FY27 snapshot. Check the NSE or BSE exchange filing for the latest dividend announcement from Sudeep Pharma.

What is the outlook for Sudeep Pharma after Q1 results FY27?

Ans. Following the Sudeep Pharma Q1 results FY27, analysts will track whether the growth in revenue and improvement in profit continue into Q2 FY27 (September quarter), along with margin trends and management guidance.

Is Sudeep Pharma a good buy after Q1 results FY27?

Ans. The Sudeep Pharma Q1 results FY27 show revenue of Rs 158 Cr and PAT of Rs 40 Cr. Investment decisions should be based on valuation relative to earnings trajectory, not a single quarter. Consult a SEBI-registered advisor before investing.